UDP Glucuronosyltransferase 1A1 (UGT1A1) Genotyping
UGT1A1 codes for the enzyme uridine diphosphate glucuronyltransferase (UGT) isoform 1A1. This enzyme converts small water-insoluble lipophilic molecules into water-soluble metabolites by glucuronidation, most notably steroids, bilirubin, and drugs, thereby ameliorating their excretion. Polymorphisms involving UGT1A1 lead to altered enzyme activity and are a result of insertions, deletions, frame-shift mutations and single nucleotide changes involving the promoter region, exon and intron regions of the gene. Wild type allele UGT1A1*1 has six TA repeats in the promoter region while the most common mutant allele UGT1A1*28 has seven TA repeats. Alleles *36 and *37 also involve TA repeats in the promoter region. Alleles *6 and *27 involve point mutations in the exon 1. Allele *36 confers an increased activity on UGT1A1 while all others result in a phenotype with reduced enzyme activity, thereby resulting in accumulation of its substrates.
Gilbert’s syndrome is a hereditary condition characterized by reduced activity of UGT1A1 isoform (70-80% reduction) and presents as benign hyperbilirubinemia. It is most commonly associated with *28 homozygous genotype. Homozygous *6 (G71R point mutation) can also cause Gilbert’s syndrome and is more commonly seen in Asians. Crigler-Najjar syndrome type II is a very rare condition clinically similar to Gilbert’s syndrome and is associated with *37 genotype.
SN-38 is the active metabolite of the chemotherapeutic drug irinotecan used in the treatment of colorectal cancer. SN-38 is inactivated by glucuronidation and is catalyzed by UGT enzymes, remarkably by UGT1A1 isoform. If the patient has a *28/*28 genotype, SN-38 will not be inactivated and it manifests with toxic adverse reactions which include severe neutropenia and severe diarrhea. By genotyping the patients’ UGT1A1, irinotecan dosage can be modified and these adverse reactions can be greatly reduced. The FDA has approved the inclusion of UGT1A1 genotype associated risk of toxicity on the irinotecan package insert. Patients homozygous for *1 allele have a lower risk of developing diarrhea and neutropenia and hence can receive standard doses of irinotecan while those homozygous for *28 allele carry a significant risk for the adverse effects, requiring dose reduction. Patients who are heterozygous carry an intermediate risk and the dose requirements are determined by clinical criteria.
- To plan therapeutic regimens for patients who need irinotecan therapy
- To confirm clinical diagnosis of Gilbert’s syndrome or Crigler-Najjar syndrome
- Genotype UGT1A1 6/6 (\1/\1) would be reported as wild type (diarrhea 17 percent; neutropenia 15 percent)
- Genotype UGT1A1 6/7 (\1/\28): diarrhea 33 percent; neutropenia 27 percent
- Genotype UGT1A1 7/7 (\28/\28): diarrhea 70 percent; neutropenia 40 percent
UGT1A1*1/*1 (Wiled type) genotype and corresponds to normal UGT1A1 activity.
Buccal swab and peripheral blood (EDTA) or saliva.
Buccal swabs can be collected by rubbing the inside of the cheeks with a swab (similar to a Q-tip and generally 4 swabs).
The swabs are transported to the laboratory in a liquid medium (see manufacturer guidelines for details) or dry swab.
Peripheral blood is collected through venipuncture. A minimum of 5-10 ml of whole blood is required. The specimen is collected in a lavender top (EDTA) tube.
Stability (Blood)
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Clin Pharmacol Ther. 2011 May; 89(5):662-73. [PMID: 21412232]
- Genet Med. 2009 Jan; 11(1):21-34. [PMID: 19125129]
- Br J Cancer. 2004 Aug 16; 91(4):678-82. [PMID: 15280927]